CAS: 90196-32-0; 2-Chloro-5-Ethylpyridine

相似化合物

68700-93-6 39891-09-3 18368-64-4

上下游产品

CAS号23220-68-0 (E)-3-(PYRROLID... | CAS号56176-56-8 1-(1-butenyl)py...

5-溴-2-氯吡啶置于四(三苯基膦)钯,Crabtree'S Catalyst,氢气,Sodium Carbonate体系中,用 甲醇,乙二醇二甲醚,水 作为反应溶剂,84.0 °C,101.33 Kpa 条件下,反应 18.0H,反应生成 2-氯-5-乙基吡啶
参考文献:一种2-氯-5-乙基吡啶的制备方法
标题:一种2-氯-5-乙基吡啶的制备方法
摘要:本发明公开了一种合成2‑氯‑5‑乙基吡啶的方法,通过suzuki反应将2‑氯‑5‑溴吡啶或通过wittig反应将2‑氯‑5‑甲酰基吡啶转化为2‑氯‑5‑乙烯基吡啶;进一步采用式(I)结构的含铱催化剂选择性加氢,其中r为环己基,正丁基或苯基,L为吡啶或非饱和含氮卡宾,将2‑氯‑5‑乙烯基吡啶转化为2‑氯‑5‑乙基吡啶.本发明方法具有选择性高,收率高和纯化方便的优点.

专利信息

专利号:US-7919627-B2
优先权日:2005-05-02
标题:Processes for the preparation of hydroxylamines
发明人：TANG DATONG; QIU YAO-LING; KIM HEEJIN; OR YAT SUN; WANG ZHE
权利人:ENANTA PHARM INC
摘要:The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (Ia):

专利号:WO-2011161615-A1
优先权日:2010-06-24
标题 :5-lipoxygenase inhibitors
发明人：VERMA ASHWANI KUMAR; MALHOTRA SANJAY; MARIMGANTI SRINIVASA; RAY ABHIJIT; GUPTA SUMAN; SRIVASTAVA PUNIT; DASTIDAR SUNANDA GHOSH
权利人:RANBAXY LAB LTD; VERMA ASHWANI KUMAR; MALHOTRA SANJAY; MARIMGANTI SRINIVASA; RAY ABHIJIT; GUPTA SUMAN; SRIVASTAVA PUNIT; DASTIDAR SUNANDA GHOSH
摘要:The present invention relates to pyrazole derivatives of formula 1 and to process as for their synthesis as 5-lipoxygenase (5-LO) inhibitors. The present invention also relates to pharmacological compositions containing these pyrazole derivatives, as well as, methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, Type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders.